Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Interest Expenses (2016 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Interest Expenses for 9 consecutive years, with $473000.0 as the latest value for Q4 2025.

  • Quarterly Interest Expenses changed 0.0% to $473000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.9 million through Dec 2025, changed 0.27% year-over-year, with the annual reading at $1.9 million for FY2025, 0.27% changed from the prior year.
  • Interest Expenses hit $473000.0 in Q4 2025 for Rocket Pharmaceuticals, roughly flat from $473000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $1.7 million in Q1 2021 to a low of $251000.0 in Q2 2021.
  • Historically, Interest Expenses has averaged $524500.0 across 5 years, with a median of $470500.0 in 2023.
  • Biggest five-year swings in Interest Expenses: tumbled 85.95% in 2021 and later skyrocketed 85.26% in 2022.
  • Year by year, Interest Expenses stood at $463000.0 in 2021, then increased by 0.86% to $467000.0 in 2022, then increased by 0.64% to $470000.0 in 2023, then grew by 0.64% to $473000.0 in 2024, then changed by 0.0% to $473000.0 in 2025.
  • Business Quant data shows Interest Expenses for RCKT at $473000.0 in Q4 2025, $473000.0 in Q3 2025, and $473000.0 in Q2 2025.